文献速递炎症性肠病

乌帕替尼在克罗恩病中实现临床和内镜结局,无论既往是否暴露于生物制剂

Upadacitinib Achieves Clinical and Endoscopic Outcomes in Crohn's Disease Regardless of Prior Biologic Exposure.
PubMed 文献 · Clin Gastroenterol Hepatol · 2024-03-15

这项事后分析基于三项随机对照试验,评估乌帕替尼在克罗恩病患者中按既往生物制剂失败状态分层的疗效。共纳入1021例患者,733例(71.8%)有既往生物制剂失败史。结果显示,无论既往是否暴露于生物制剂,乌帕替尼治疗组在临床缓解和内镜应答率上均高于安慰剂组。

要点

  • 诱导期乌帕替尼45 mg在无失败史者临床缓解54.0% vs 安慰剂28.3%,有失败史者42.2% vs 14.1%。
  • 维持期乌帕替尼30 mg在有失败史者中临床缓解42.5% vs 安慰剂8.7%,内镜应答38.9% vs 4.0%。
  • 无既往生物制剂失败史的患者不良事件少于有失败史者。

核心结论

  • 乌帕替尼治疗组在临床和内镜结局上的绝对缓解率,在无既往生物制剂失败史患者中高于有失败史患者。
  • 无论既往是否暴露于生物制剂,乌帕替尼组在临床和内镜改善率上均高于安慰剂组。

研究设计与样本

  • 事后分析,纳入U-EXCEL(NCT03345849)、U-EXCEED(NCT03345836)诱导试验和U-ENDURE(NCT03345823)维持试验。
  • 患者随机接受安慰剂或乌帕替尼45 mg治疗12周(诱导期);乌帕替尼45 mg临床应答者进入U-ENDURE,重新随机接受安慰剂、乌帕替尼15 mg或乌帕替尼30 mg治疗52周。
  • 共1021例患者,其中733例(71.8%)有既往生物制剂失败史。

主要发现

  • 诱导期临床缓解(基于排便频率/腹痛评分):无失败史者乌帕替尼组54.0% vs 安慰剂组28.3%;有失败史者42.2% vs 14.1%。
  • 诱导期内镜应答:无失败史者52.0% vs 16.2%;有失败史者35.7% vs 5.3%。
  • 维持期最大治疗效应见于有既往生物制剂失败史且接受乌帕替尼30 mg的患者:临床缓解无失败史58.5% vs 32.7%,有失败史42.5% vs 8.7%;内镜应答无失败史43.9% vs 17.9%,有失败史38.9% vs 4.0%。
  • 无既往生物制剂失败史的患者不良事件少于有失败史者。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Upadacitinib, an oral Janus kinase inhibitor, achieved significantly higher rates of clinical remission and endoscopic response vs placebo during induction (U-EXCEL [NCT03345849], U-EXCEED [NCT03345836]) and maintenance (U-ENDURE [NCT03345823]) treatment in patients with moderate-to-severe Crohn's disease. Prior biologic failure is often associated with reduced responses to subsequent therapies. This post hoc analysis assessed upadacitinib efficacy by prior biologic failure status. METHODS: Patients were randomized to placebo or upadacitinib 45 mg (UPA45) for 12 weeks (induction). UPA45 clinical responders were enrolled in U-ENDURE and rerandomized to placebo, upadacitinib 15 mg, or upadacitinib 30 mg (UPA30) for 52 weeks. Assessments were by prior biologic failure. RESULTS: Of 1021 patients, 733 (71.8%) had prior biologic failure. Across outcomes and subgroups, upadacitinib-treated patients achieved higher rates vs placebo. During induction, upadacitinib had higher rates vs placebo for clinical remission based on stool frequency/abdominal pain score (without failure: 54.0% vs 28.3%; with failure: 42.2% vs 14.1%) and endoscopic response (without failure: 52.0% vs 16.2%; with failure: 35.7% vs 5.3%). In maintenance, the greatest treatment effect (upadacitinib vs placebo) was among patients with prior biologic failure treated with UPA30 (clinical remission without failure: 58.5% vs 32.7%; with failure: 42.5% vs 8.7%; endoscopic response without failure: 43.9% vs 17.9%; with failure: 38.9% vs 4.0%). Patients without vs with prior biologic failure had fewer adverse events. CONCLUSIONS: Upadacitinib led to higher absolutes rates of clinical and endoscopic outcomes in patients without vs with prior biologic failure. Patients treated with upadacitinib achieved greater rates of clinical and endoscopic improvements vs placebo, regardless of prior biologic exposure. CLINICALTRIALS: gov: NCT03345849, NCT03345836, NCT03345823.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Peyrin-Biroulet L, Panaccione R, Louis E, et al. Upadacitinib Achieves Clinical and Endoscopic Outcomes in Crohn's Disease Regardless of Prior Biologic Exposure. Clin Gastroenterol Hepatol. 2024. PMID: 38492904. doi:10.1016/j.cgh.2024.02.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。